These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

481 related items for PubMed ID: 29844695

  • 21. Biosimilars of adalimumab: the upcoming challenge in IBD.
    Fiorino G, Gilardi D, Correale C, Furfaro F, Roda G, Loy L, Argollo M, Allocca M, Peyrin-Biroulet L, Danese S.
    Expert Opin Biol Ther; 2019 Oct; 19(10):1023-1030. PubMed ID: 30601098
    [Abstract] [Full Text] [Related]

  • 22. Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA.
    Gómez-Labrador C, Ricart E, Iborra M, Iglesias E, Martín-Arranz MD, de Castro L, De Francisco R, García-Alonso FJ, Sanahuja A, Gargallo-Puyuelo CJ, Mesonero F, Casanova MJ, Mañosa M, Rivero M, Calvo M, Sierra-Ausin M, González-Muñoza C, Calvet X, García-López S, Guardiola J, Arias García L, Márquez-Mosquera L, Gutiérrez A, Zabana Y, Navarro-Llavat M, Lorente Poyatos R, Piqueras M, Torrealba L, Bermejo F, Ponferrada-Díaz Á, Pérez-Calle JL, Barreiro-de Acosta M, Tejido C, Cabriada JL, Marín-Jiménez I, Roncero Ó, Ber Y, Fernández-Salazar L, Camps Aler B, Lucendo AJ, Llaó J, Bujanda L, Muñoz Villafranca C, Domènech E, Chaparro M, Gisbert JP.
    Pharmaceutics; 2024 May 08; 16(5):. PubMed ID: 38794292
    [Abstract] [Full Text] [Related]

  • 23. Advances in biologic therapy for ulcerative colitis and Crohn's disease.
    D'Haens G, Daperno M.
    Curr Gastroenterol Rep; 2006 Dec 08; 8(6):506-12. PubMed ID: 17105690
    [Abstract] [Full Text] [Related]

  • 24. Benefits of Biosimilars in the Management of Patients with Inflammatory Bowel Disease: An International Survey.
    D'Amico F, Peyrin-Biroulet L, Danese S.
    J Clin Med; 2024 May 24; 13(11):. PubMed ID: 38892780
    [Abstract] [Full Text] [Related]

  • 25. Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation.
    Whitlock SM, Enos CW, Armstrong AW, Gottlieb A, Langley RG, Lebwohl M, Merola JF, Ryan C, Siegel MP, Weinberg JM, Wu JJ, Van Voorhees AS.
    J Am Acad Dermatol; 2018 Feb 24; 78(2):383-394. PubMed ID: 29332708
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.
    Papamichael K, Van Stappen T, Jairath V, Gecse K, Khanna R, D'Haens G, Vermeire S, Gils A, Feagan BG, Levesque BG, Vande Casteele N.
    Aliment Pharmacol Ther; 2015 Nov 24; 42(10):1158-69. PubMed ID: 26365281
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Ustekinumab for the treatment of paradoxical skin reactions and cutaneous manifestations of inflammatory bowel diseases.
    Wu J, Smogorzewski J.
    Dermatol Ther; 2021 May 24; 34(3):e14883. PubMed ID: 33594811
    [Abstract] [Full Text] [Related]

  • 31. Predictive value of blood concentration of biologics on endoscopic inactivity in inflammatory bowel disease: A systematic review.
    Cao WT, Huang R, Jiang KF, Qiao XH, Wang JJ, Fan YH, Xu Y.
    World J Gastroenterol; 2021 Mar 07; 27(9):886-907. PubMed ID: 33727776
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [Pharmacology of biologic medications].
    Marusić M, Mihaljević S.
    Acta Med Croatica; 2013 Apr 07; 67(2):125-30. PubMed ID: 24471295
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars.
    Petric Z, Goncalves J, Paixao P.
    Pharmaceutics; 2022 Aug 24; 14(9):. PubMed ID: 36145514
    [Abstract] [Full Text] [Related]

  • 39. [New molecules in the treatment of inflammatory bowel disease].
    Chaparro M, Gisbert JP.
    Gastroenterol Hepatol; 2016 Aug 24; 39(6):411-23. PubMed ID: 26631943
    [Abstract] [Full Text] [Related]

  • 40. Does perioperative biological therapy increase 30-day post-operative complication rates in inflammatory bowel disease patients undergoing intra-abdominal surgery? A systematic review.
    Byrne LW, McKay D.
    Surgeon; 2021 Oct 24; 19(5):e153-e167. PubMed ID: 34581275
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.